BBIO: Multiple Priority Reviews And Rare Disease Launches Will Drive Post 2026 Upside

BridgeBio Pharma's updated analyst price target has nudged higher to about $108, with analysts pointing to continued progress for Attruby, multiple NDAs now under regulatory review, and an active rare disease pipeline as key drivers for the refined outlook.

Analyst Commentary

Recent Street research on BridgeBio Pharma highlights a mix of confidence in the company’s rare disease portfolio and some caution around competitive and payer related risks. Taken together, analysts are refining valuation targets as the Attruby launch progresses and multiple NDAs move through regulatory review.

Bullish Takeaways

• Bullish analysts are lifting price targets into a roughly US$93 to US$120 range, which signals higher implied value on the current Attruby launch and the broader rare disease pipeline.
• Several reports point to Attruby as a key foundation for BridgeBio Pharma, with recent quarters described as strong and supporting the view that the company can execute on commercialization while advancing additional programs.
• With three NDAs submitted and all described as in active regulatory review, bullish analysts see clearer execution visibility on a potential multi product launch phase, which feeds into higher longer term growth assumptions.
• Priority Review status for BBP-418 and encaleret, and commentary that no advisory committees are currently planned for these, are seen as reducing some regulatory uncertainty and supporting confidence in the company’s near term execution path.

Bearish Takeaways

• More cautious analysts flag payer related headwinds around Attruby, especially into and after the expected Vyndamax loss of exclusivity in 2031, which could pressure pricing power and limit upside for the stock.
• One major brokerage moved to a neutral stance without a price target and suggests that substantial payer efforts to promote lower cost options may weigh on how much valuation can expand from here.
• Some research keeps a neutral rating and describes the shares as potentially range bound, with BridgeBio Pharma’s pipeline viewed as mostly operational into the end of 2026, which may temper expectations for near term re rating.
• There are also modest downward adjustments to price targets in a few cases, reflecting updated models after quarterly results and signaling that not all analysts see the same upside to execution or growth assumptions.

What’s in the News for BridgeBio Pharma

• The FDA accepted BridgeBio Pharma’s New Drug Application for encaleret in autosomal dominant hypocalcemia type 1, starting a defined review timeline and positioning the therapy as a potential first in class option for this rare calcium disorder. Source: FDA NDA acceptance news.
• BridgeBio Pharma reported Q2 2026 financial results on August 10, 2026, with revenue supported by ATTR-CM therapy Attruby and updates that three lead programs, BBP-418, encaleret, and oral infigratinib, have NDAs under Priority Review at the FDA. Source: Q2 2026 earnings and corporate update.
• The company closed a US$1b preferred equity financing and put shelf registrations in place for up to about US$2.21b in common stock capacity to fund pipeline development and potential commercialization activity. Source: Q2 2026 earnings and financing disclosure.
• The FDA granted Priority Review to BBP-418 for limb girdle muscular dystrophy type 2I/R9 with a PDUFA target date of November 27, 2026, after the Phase 3 FORTIFY trial met all primary and secondary endpoints at the 12 month interim analysis. Source: BBP-418 Priority Review announcement.
• New real world and clinical data for Attruby and additional Phase 3 results for oral infigratinib in achondroplasia were released in peer reviewed publications and conference presentations, adding detail on kidney function, cardiovascular outcomes, growth measures, and quality of life in the company’s core rare disease programs. Source: recent product related announcements and conference data disclosures.

Valuation Changes for BridgeBio Pharma

• Fair Value has risen slightly from $105.26 to $107.67, reflecting a modest uplift in the central valuation estimate for BridgeBio Pharma.
• Discount Rate has moved up from 7.38% to 7.65%, which points to a slightly higher required return being applied to future cash flows.
• Revenue Growth now sits at 62.14% compared with 67.22% previously, indicating a more restrained growth assumption in the latest model.
• Profit Margin has edged higher from 32.90% to 34.21%, suggesting a somewhat stronger long run profitability profile for the company.
• Future P/E has fallen from 30.67x to 27.12x, implying that the updated framework applies a lower earnings multiple to BridgeBio Pharma’s forward earnings base.